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Background: The prevailing view that advocates long-term hormonal follow-up of adrenal incidentalomas is currently
under debate. The purpose of the present study was to examine all adrenal incidentalomas presented during five years
to a single centre. We hypothesized that 24-month biochemical follow-up in patients with an initial normal screening
would fail to increase the sensitivity in finding hormone producing tumours.
Methods: The present study is a retrospective register based cohort study of 194 patients referred to the Department
of Endocrinology at Södersjukhuset between the years 2006–2010. Computerized medical records were used to find
and extract information on patients with newly discovered adrenal incidentalomas. The sensitivity, specificity, positive
predictive value and negative predictive value were calculated to evaluate the validity of an initial normal screening
when used to identify individuals with hormone producing tumours.
Results: Of the incidentalomas 94% consisted of benign, non-functioning tumours. Three patients were diagnosed with
cortisol hypersecretion and one with pheochromocytoma. The sensitivity, specificity, positive predictive value and
negative predictive value of an initial complete negative screening to predict a hormone producing tumour were
100%, 63%, 12% and 100%, respectively.
Conclusion: Patients with an initially normal hormonal screening may not need further biochemical follow-up.
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An adrenal incidentaloma is a tumour in the adrenal
gland accidentally discovered when a patient undergoes
radiological investigation for other reasons than sus-
pected adrenal disease [1]. The mean prevalence is 2.3%
and increases with age to 6.9% in patients above 70 years
[2]. The prevalent occurrence together with the in-
creased use of radiological investigation has resulted in
the frequent incidental discovery of asymptomatic ad-
renal masses. Even though the majority of incidentalo-
mas are benign and non-hyperfunctioning, careful
radiological and hormonal investigations are needed in
order to identify malignant and hormone producing tu-
mours [3]. The management often includes biochemical* Correspondence: buster.mannheimer@sodersjukhuset.se
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unless otherwise stated.hormonal surveillance maintained for several years
which may be associated with significant emotional dis-
tress [4] and financial [5] costs in a group of patients
where the vast majority turn out to be healthy. The pre-
vailing view that advocates long-term hormonal follow-
up [3,6,7] has therefore recently been challenged [8].
However, the evidence remains scarce. The present study
examined all adrenal incidentalomas presented to a single
centre between 2006 and 2010. We hypothesized that
long-term biochemical follow-up in patients with an initial
normal biochemical screening would fail to increase the
sensitivity in finding hormone-producing tumours.Methods
Consent statement
This was a retrospective database study that included
data on 294 patients treated at Södersjukhuset during a
period of 5 years. Hence, we did not interfere with theal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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view was also supported by the Regional Ethics Committee
in Stockholm, Karolinska Institute, which waived the need
for written informed consent from the participants and
approved the study as a whole.
Setting and participants
The present study is a retrospective register based co-
hort study of patients referred to the Department of
Endocrinology at Södersjukhuset between the 1st of
January 2006 and the 31st of December 2010. Södersju-
khuset is a hospital providing secondary, emergency and
elective care to 600 000 inhabitants in Stockholm,
Sweden. All patients with a new incidentally discovered
adrenal mass was selected. Computerized medical records
were used to find patients with any of the International
Classification of Diagnoses (ICD) 10 codes D441 (tumour
of unclear origin in adrenal gland), D350 (benign tumour
in adrenal gland), E279 (adrenal disease unspecified) or
C741 (malignant tumour in adrenal gland) were screened
for possible inclusion. Patients with previously known
adrenal tumour/s or who were investigated on suspi-
cion of adrenal disease, and patients with previously
known co-existing malignancy or signs of extra adrenal
malignancy at baseline were excluded. Patients with a
previous diagnosis of malignancy, but no evidence of
present malignancy at the time the adrenal incidenta-
loma was detected were eligible for inclusion. The
Swedish national guidelines during the studied period
recommended initial radiological and hormonal evalu-
ation and (if both normal) to be followed by a new bio-
chemical evaluation 24 months later. The hormonal
evaluation comprised of investigating cortisol and cat-
echolamine secretion in all patients. In patients with
hypertension or hypokalaemia measurement of aldoster-
one and renin secretion was added (see below). To im-
prove the evaluation of the 24-month follow-up, patients
who had not completed the investigation were approached
and offered to do so. Fourteen patients subsequently
underwent complementary testing. Follow-up information
was collected until the 31st of October 2013.
The study was approved by the Ethics Committees of
the Karolinska Institutet, Stockholm, Sweden.
Variables and datasources
All information in the present study, including the
biochemical screening and radiological tumour charac-
teristics (tumour size, attenuation and washout) from
the initial visit as well as from follow-up visits, were col-
lected from the computerized medical files. Existence of
co-morbidity was only registered for the initial visit. The
biochemical data was retrieved from the laboratory data-
base and included: a/ aldosterone, evaluated using the
aldosterone/renin ratio (ARR), b/ catecholamine secretionevaluated by measurement of plasma metanephrines or a
24-hour urine collection of catecholamines, and c/ evalu-
ation of cortisol secretion. The initial screening for cortisol
hypersecretion was performed using the 1 mg overnight
dexamethasone suppression test (DST) (n = 107) or a 24-
hour urine collection of cortisol (n = 45). In patients
with deviating results of this initial screening and/or
with clinical signs of cortisol hypersecretion, one or
several additional tests were assessed. A cortisol hyperse-
cretion was defined as any two of the following tests be-
ing abnormal: a/ DST, b/ a 24-hour urine collection of
cortisol, c/morning plasma adrenocorticotropic hormone
(ACTH) and, d/ a circadian rhythm of serum cortisol in
the absence of evidence of severe stress, alcoholism, de-
pression, or drug-drug interactions. Cushing’s syndrome
was defined as clinical signs typical of Cushing’s syn-
drome (moon face, buffalo hump, hypertension, osteopor-
osis, diabetes mellitus) together with two tests of cortisol
secretion being abnormal. Subclinical Cushing was defined
as two abnormal tests in an individual without clinical
signs of Cushing’s syndrome.
Laboratory methods and cut-off values
All analyses were performed at the Karolinska University
Laboratory. Serum cortisol was measured by Electro-
ChemiLuminiscence Immunoassay (ECLIA) (Roche
Diagnostics). DST was considered normal when morning
cortisol fell below 50 nmol/L. The circadian rhythm was
performed in hospitalised patients and considered normal
when the midnight cortisol value was below 50 nmol/L.
Urine cortisol was measured by high performance liquid
chromatography (Waters Quattro Premier MS/MS-system
with Waters Acquity UPLC). The normal range was
40 nmol/d – 170 nmol/24 h. Plasma renin was assessed
with the Electrabox CISBIO IRMA kit. ACTH was
measured by ElectroChemiLuminiscence Immunoassay
(ECLIA) (Roche Diagnostics). Morning ACTH concentra-
tions <2 pmol/L were considered subnormal. Plasma al-
dosterone was determined using Siemens Coat-A-Count
RIA kit (Siemens Ltd). An ARR >100 was considered to
indicate autonomous aldosterone production [9,10]. The
24-hour urine collections of catecholamines were mea-
sured by high performance liquid chromatography (HPLC).
The normal range for urinary adrenalin and noradrenalin
was <80 nmol/24 h and <400 nmol/24 h, respectively [11].
Fasting plasma metoxycatecholamines were assessed by re-
versed phase chromatography (LC-MS/MS Xevo QT with
Acquity UPLC, from Waters Sweden AB). The normal
ranges for p-metoxyadrenaline and p-metoxynoradrenaline
were <0.3 nmol/L and <0.6 nmol/L, respectively.
Radiological classification of adrenal lesions
Lesions were classified as benign if they were small
(<3 cm) and had radiological features consistent with
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Figure 1 Patient flow chart.
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lipid-rich with 10 or less Hounsfield units (HU) on
unenhanced CT, and for MRI a clear signal intensity
decrease on opposed-phase images, compared with in-
phase images or if they had other typical benign charac-
teristics such as a thin-walled cyst, myelolipoma or
adrenal haemorrhage. Lipid poor (over 10 HU on unen-
hanced series with an absolute washout with late series
measured 15 minutes after contrast injection of more
than 50 per cent) small adenomas and large (≥3 cm)
lipid rich adenomas were considered benign if they were
stationary (<20% or <5 mm increase in diameter) at
follow-up of at least 12 months. Lesions that were not
evaluated with regard to lipid content (fifty patients that
were predominantly included before a change of the
local guidelines 2008) were considered benign if they
were stationary at 12 months follow-up.
Statistical methods
To evaluate the validity of an initial normal screening
for the identification of individuals with hormone produ-
cing tumours, the sensitivity, specificity, positive predict-
ive value and negative predictive value were calculated.
The distribution of location (i.e. left or right) of unilat-
eral incidentalomas was presented as proportions (%) as-
sociated with 95% confidence intervals (CI) including
continuity corrections. The chi-square test was applied
to test the differences in proportion of different cardio-
metabolic risk factors in patients with and without bio-
chemical signs of cortisol hypersecretion. P-values <0.05
were considered significant. Proportions of locations of
unilateral incidentalomas were calculated using VassarStats
[12]. All other calculations were performed in IBM SPSS
Statistics 22.0 (SPSS Inc., Chicago, IL, USA).
Results
Individuals who presented with a first time diagnosis
of adrenal incidentaloma were considered eligible for
inclusion in the study (n = 255). Patients with known co-
existing malignancy (n = 26), with previously known
adrenal tumour/s (n = 14), patients who had been inves-
tigated on suspicion of adrenal disease (n = 13), or had
had signs of extra-adrenal malignancy at baseline (n = 8)
were excluded, resulting in a study population of 194 pa-
tients (Figure 1).
The patient and adrenal imaging characteristics at
the time of the initial visit to the Department of
Endocrinology are presented in Table 1. The mean
age (SD) was 65 years (12), and 63% were women.
Left-sided adrenal tumour was found in 72% of the
156 patients with unilateral incidentaloma. Bilateral inci-
dentalomas were present in 19% of the patients. The
mean follow-up time (range) was 24 (0–59) months.
Seven individuals (5%) deceased during the follow-upperiod due to non-adrenal malignancy (n = 2), cardiovas-
cular disease (n = 1), sepsis (n = 1), pneumonia (n = 1), or
unknown reason (n = 2).
The outcome of the investigations is presented in
Table 2. Of the adrenal incidentalomas with a known
diagnosis, 94% were benign, non-hyperfunctioning tu-
mours. Two patients were diagnosed with cortisol
hypersecretion (one underwent adrenalectomy while
the other have hitherto been conservatively treated),
and one with pheochromocytoma. In addition, 6 pa-
tients underwent surgery due to large tumour size where
subsequent histological examination revealed ganglio-
neuroma (n = 1), hemorrhagic cyst (n = 1), benign aden-
oma (n = 3), and accessory spleen (n = 1, i.e. no adrenal
tumour). No cases of hyperaldosteronism or adrenocorti-
cal cancer were identified.
Table 1 Patient and adrenal characteristics at baseline
(n patients = 194, n incidentalomas = 231)
Patient characteristics
Mean age (SDa) 65 (12)
Women, n 122 (63%)
Co-morbidity
Hypertension, n 108 (56%)
Hyperlipidemia, n 52 (27%)
Diabetes (type 2), n 41 (21%)
COPDb, n 33 (17%)
Ischemic heart disease, n 24 (12%)
Previous history of malignancy, but no evidence of
present disease at the time the adrenal incidentaloma
was detected
24 (12%)
Stroke, n 11 (6%)
Heart failure, n 7 (4%)
Peripheral arterial diseasecss n 7 (4%)
Adrenal characteristics
Unilateral incidentaloma (right), n 44 (23%)
Unilateral incidentaloma (left), n 111 (57%)
Unilateral incidentaloma (side not stated), n 1 (0.5%)
Bilateral incidentalomas, n 37 (19%)
Mean size at initial adrenal imaging, mm (SD1)c 21 (9.3)
Lipid rich (≤10 Hounsfield units)d 79 (81%)
Lipid poor (>10 Hounsfield units) with an absolute
washout < 50% indicating benign tumoure
9 (45%)
Lipid poor (>10 Hounsfield units) with an absolute
washout≥ 50% indicating malign tumoure
2 (10%)
aStandard Deviation.
bChronic Obstructive Lung Disease.
cFor incidentalomas examined with adrenal imaging where size was
stated (n = 218).
dFor incidentalomas were attenuation and washout was quantified (n = 98).
eFor incidentalomas were both attenuation and washout were quantified (n = 20).
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testing both at baseline and at follow up. All three
hormone-producing tumours were found among the 25
patients with an abnormal hormonal screening at base-
line. Among the 38 patients with an initial normal
complete hormonal screening no hormone overproduc-
tion was found at 24 months follow-up. Thus, the sensi-
tivity, specificity, positive predictive value and negative
predictive values of an initial complete negative screen-
ing to predict a hormone producing tumour were 100%,
63%, 12% and 100%, respectively (Figure 2). To further
evaluate the biochemical testing we investigated respect-
ive hormonal axis separately. For example, when exam-
ining the cortisol axis, we included all patients that were
investigated adequately with regard to cortisol excretion
both at baseline and at 24 months follow-up, even
though data on catecholamine or aldosterone secretionwas missing. Thus, among 57, 63 and 66 patients with
an initial normal cortisol, aldosterone and catecholamine
evaluation respectively at baseline, no case of hormonal
hyperproduction was discovered at follow-up.
Discussion
In the present study 94% of the incidentalomas consisted
of benign, non-hyperfunctioning adenomas. No adreno-
cortical cancer or adrenal metastasis was found. None
of the patients with an initial negative biochemical
screening developed hormonal hypersecretion during
the follow-up.
Our results are in accordance with the investigation by
Muth et al. [13]. In contrast, other studies have indi-
cated a potential of hormonal activation in patients with
an initial negative screening and therefore support long-
term hormonal monitoring [14-16]. The most common
disorder reported during follow-up is the occurrence of
autonomous cortisol secretion in patients without clin-
ical signs of Cushing syndrome, i.e. subclinical Cushing
syndrome (SCS), while the onset of catecholamine over-
production or hyperaldosteronism after initial negative
screening is very rare [2]. Given that the investigation of
cortisol secretion is associated with methodological
problems causing a high proportion of false positive re-
sults [17], that cortisol levels may vary over time [18],
and the questionable benefit of performing adrenalec-
tomy in patients with SCS [19], conservative treatment
may be a better strategy.
The high proportion of benign, non-hyperfunctioning
adenomas of 94% found in the present study was in ac-
cordance with some previous studies but not all. Two
Swedish prospective studies estimated corresponding
prevalences of 96% (218/226) and 91% (347/381) re-
spectively [13,20], while most other studies indicate a
prevalence around approximately 80% [2]. The explan-
ation of these discrepancies is probably that some stud-
ies may be biased towards an unhealthier group of
patients treated in specialised care units with a higher
prevalence of hormonal aberrations.
The age of the individuals involved in the current
study range from 34 to 94 with few individuals below
50 (n = 16) years and the results of the study may
therefore not be extrapolated to a younger popula-
tion. The prevalence of adrenal incidentalomas is
rare in individuals < 40 years old, and the chance of
finding a hormonal disturbance or congenital condi-
tion such as congenital adrenal hyperplasia may be
increased [21] but this has to be studied further.
An interesting finding was the discovery that left-sided
adrenal incidentalomas were more than twice as com-
mon as right-sided ones. This is in contrast to previous
studies [22,23], and it could be speculated that the liver
impairs the visualising of the right adrenal gland.
Table 2 Outcome of the investigations of 231 incidentalomas in the study population (n = 194)





Adenomas 154 (91%) N/A
Myelolipoma 3 (1.8%) N/A
Ganglioneuroma 1 (0.6%) Diagnosis through PADc. Surgery.
Hemorrhagic cyst 1 (0.6%) Diagnosis through PAD. Surgery.
Hematoma 1 (0.6%)
Malignant or functioning tumours 3 (1.8) N/A
Cortisol hypersecretion 2 (1.2%) 1 patient underwent surgery due to Cushings
syndrome, and PAD showed adrenal hyperplasia.
Surgery (n = 1).
1 patient s were diagnosed with subclinical
Cushing but not judged to benefit from
surgery and therefore conservatively treated
Conservative treatment (n = 1)
Pheochromocytoma 1 (0.6%) Confirmed with PAD Surgery.
No adrenal tumour 6 (3.5%) Further investigation diagnosed: sarcoma (n = 1),
renal cyst (n = 1), ventricular gut diverticulum
(n = 1), pleating of the tail of pancreas (n = 1),
accessory spleen (n = 1), and no tumour-like
structure was found in the adrenal CT (n = 1).
Referred to another department
(n = 1, Department of Sarcoma).
Surgery due to large tumour size,
where PAD showed an accessory
spleen (n = 1).
Unknown 62 (N/A) Unknown diagnosis due to absence of adequate
follow-up (n = 43), death (n = 10) the patient
declining further investigation (n = 6), or still
ongoing investigations (n = 3)
N/A
aGiven percentages are based on patients with a known diagnosis (n = 170).
bNon Applicable.
cPathological Anatomic Diagnosis.
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incidentalomas diagnosed during a five year period may
have hampered the study to some extent. Due to a shift
towards the use of the overnight low-dose (1 mg) DST
and plasma metanephrines rather than 24-hour urinary
collections of cortisol and catecholamines, the patients
were not uniformly investigated which may question the
validity of the data. For various reasons, the number of
patients eligible to study the validity of an initial normal
hormonal screening to identify hormone-producing tu-
mours was reduced to 63 which weakens the conclu-
sions (Figure 1). On the other hand, a strength with thea (3) b (22)

























Figure 2 The validity of an initial hormonal screening to identify indipresent study is that the included patients were referred
from a defined catchment area where Södersjukhuset
represents the only Endocrine out-patient clinic investi-
gating patients with adrenal incidentalomas. The study
population may therefore represent the population in
general very well. This is in contrast to some previous
studies performed at tertiary centers which increases
the risk for selection bias towards a less healthy study
population, and findings of rare syndromes [2,21]. In
order to further evaluate the value of long term bio-
chemical follow up we do suggest prospective larger
studies. a / (a + c) = 100%
 d / (b + d) = 63%
dictive value = a / (a + b) = 12%
edictive value = d / (c + d) = 100%
viduals with hormonal producing tumours in 63 patients.
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The vast majority of the adrenal incidentalomas were
benign, hormonally inactive adenomas. For patients with
an initial normal biochemical investigation, the 24-
month hormonal follow-up did not result in the finding
of any additional hormonally active tumours. This study
indicates that patients with an initial normal hormonal
screening may not need further biochemical follow-up.
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